{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T07:52:42Z","timestamp":1648540362868},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00417-020-04667-y","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T03:42:41Z","timestamp":1586317361000},"page":"1405-1410","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic"],"prefix":"10.1007","volume":"258","author":[{"given":"Cagdas","family":"Kaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"4667_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology. 116:57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology."},{"key":"4667_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"issue":"12","key":"4667_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in neovascular age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"4667_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 119:1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology."},{"issue":"11","key":"4667_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"issue":"2","key":"4667_CR6","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"4667_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E et al (2017) EYE-RISK consortium, European Eye Epidemiology (E3) consortium. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 124:1753\u20131763. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035","journal-title":"Ophthalmology"},{"key":"4667_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/bjophthalmol-2017-310822","volume":"102","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Ou WC, Croft DE et al (2018) Group T-AS: Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol 102:460\u2013464. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310822","journal-title":"Br J Ophthalmol"},{"key":"4667_CR9","unstructured":"DeCroos FC, Reed DC, Adam MK et al (2016) Prospective, multicentre investigation of aflibercept treat and extend therapy for neovascular age related macular degeneration (ATLAS study): one and two year results. Abstract presented at: the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; Seattle"},{"issue":"1","key":"4667_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","volume":"38","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Daien V et al (2018) Two year outcomes of \u2018treat and extend\u2019 intravitreal therapy using aflibercept preferentially for neovascular age related macular degeneration. Retina. 38(1):20\u201328. https:\/\/doi.org\/10.1097\/IAE.0000000000001496","journal-title":"Retina."},{"issue":"8","key":"4667_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/bjopthalmol-2018-311852","volume":"103","author":"RW Essex","year":"2019","unstructured":"Essex RW, Nguyen V, Daien V et al (2019) Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. Br J Ophthalmol 103(8):1158\u20131162. https:\/\/doi.org\/10.1136\/bjopthalmol-2018-311852","journal-title":"Br J Ophthalmol"},{"key":"4667_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/OPTH.S59982","volume":"8","author":"MM Michelotti","year":"2014","unstructured":"Michelotti MM, Abugreen S, Kelly SP et al (2014) Transformational change: nurses substituting for ophthalmologists for intravitreal injections - a quality-improvement report. Clin Ophthalmol 8:755\u2013761. https:\/\/doi.org\/10.2147\/OPTH.S59982","journal-title":"Clin Ophthalmol"},{"key":"4667_CR13","first-page":"32","volume":"129","author":"P Samalia","year":"2016","unstructured":"Samalia P, Garland D, Squirrell D (2016) Nurse specialists for the administration of antivascular endothelial growth factor intravitreal injections. N Z Med J 129:32\u201338","journal-title":"N Z Med J"},{"issue":"9900","key":"4667_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/SO140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding P, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 382(9900):1258\u20131267. https:\/\/doi.org\/10.1016\/SO140-6736(13)61501-9","journal-title":"Lancet."},{"key":"4667_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 121:193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011","journal-title":"Ophthalmology."},{"key":"4667_CR16","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB (2009) \u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina 29:1424\u20131431. https:\/\/doi.org\/10.1097\/IAE.0b013e3181bfbd46","journal-title":"Retina"},{"key":"4667_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","volume":"30","author":"M Engelbert","year":"2010","unstructured":"Engelbert M, Zweifel SA, Freund KB (2010) Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 30:1368\u20131375. https:\/\/doi.org\/10.1097\/IAE.0b013e3181d50cbf","journal-title":"Retina."},{"key":"4667_CR18","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH et al (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 117:2134\u20132140. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.032","journal-title":"Ophthalmology."},{"key":"4667_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ajo.2011.08.011","volume":"153","author":"G Shienbaum","year":"2012","unstructured":"Shienbaum G, Gupta OP, Fecarotta C et al (2012) Bevacizumab for neovascular age-related macular degeneration using a treat and-extend regimen: clinical and economic impact. Am J Ophthalmol 153:468\u2013473. https:\/\/doi.org\/10.1016\/j.ajo.2011.08.011","journal-title":"Am J Ophthalmol"},{"key":"4667_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/eye.2012.174","volume":"26","author":"AT Fung","year":"2012","unstructured":"Fung AT, Kumar N, Vance SK et al (2012) Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent\/recurrent macular fluid, 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond) 26:1181\u20131187. https:\/\/doi.org\/10.1038\/eye.2012.174","journal-title":"Eye (Lond)"},{"key":"4667_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","volume":"33","author":"N Toalster","year":"2013","unstructured":"Toalster N, Russell M, Ng PA (2013) A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age related macular degeneration. Retina. 33:1351\u20131358. https:\/\/doi.org\/10.1097\/IAE.0b013e3182831265","journal-title":"Retina."},{"issue":"8","key":"4667_CR22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","volume":"34","author":"F Abedi","year":"2014","unstructured":"Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH (2014) Anti-VEGF treatment in neovascular age-related macular degeneration: a treat and-extend protocol over 2 years. Retina 34(8):1531\u20131538. https:\/\/doi.org\/10.1097\/IAE.0000000000000134","journal-title":"Retina"},{"issue":"5","key":"4667_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/IAE.0000000000000033","volume":"34","author":"RB Rush","year":"2014","unstructured":"Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE (2014) Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Retina. 34(5):846\u2013852. https:\/\/doi.org\/10.1097\/IAE.0000000000000033","journal-title":"Retina."},{"issue":"2","key":"4667_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajo.2014.05.007","volume":"158","author":"RB Rush","year":"2014","unstructured":"Rush RB, Rush SW, Aragon AV 2nd, Ysasaga JE (2014) Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Am J Ophthalmol 158(2):337\u2013344. https:\/\/doi.org\/10.1016\/j.ajo.2014.05.007","journal-title":"Am J Ophthalmol"},{"key":"4667_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 122:146\u2013152. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.041","journal-title":"Ophthalmology."},{"issue":"1","key":"4667_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","volume":"159","author":"N Rayess","year":"2015","unstructured":"Rayess N, Houston SK III, Gupta OP et al (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159(1):3\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2014.09.011","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4667_CR27","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D et al (2015) Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 122(6):1212\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.009","journal-title":"Ophthalmology."},{"issue":"7","key":"4667_CR28","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1167\/iovs.08-2970","volume":"50","author":"UE Wolf-Schnurrbusch","year":"2009","unstructured":"Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK et al (2009) Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 50(7):3432\u20133437. https:\/\/doi.org\/10.1167\/iovs.08-2970","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-020-04667-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T23:39:57Z","timestamp":1617838797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-020-04667-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4667"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04667-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed with studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"JGG advises several pharmaceutical companies (Alcon, Allergan, Bayer, Novartis) and participates in a number of international, multicentre clinical studies in the fields of AMD and diabetic retinopathy that are sponsored by some of these companies (Chengdu Kanghong, Novartis, and Bayer). These activities had no bearing on the study that gave rise to the submitted article for which JGG received neither direct nor indirect financial support; nor does he have any conflicts of interest regarding the presented data. The other authors have no potential conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}